From the Research
Ibrutinib and Prostate-Specific Antigen (PSA) Levels
- There is no direct evidence from the provided studies that ibrutinib elevates Prostate-Specific Antigen (PSA) levels 1, 2, 3, 4, 5.
- A study on tyrosine kinase inhibitors, including imatinib and nilotinib, found that these drugs can affect PSA titers independent of prostate growth or volume 2.
- Another study found that Bruton's tyrosine kinase (BTK) inhibitors, such as ibrutinib, may have a potential role in the treatment of prostate cancer, but it does not mention the effect of ibrutinib on PSA levels 3.
- The remaining studies do not provide relevant information on the effect of ibrutinib on PSA levels 1, 4, 5.
Related Studies
- A study on the treatment of chronic prostatitis found that treatment with antibiotics and anti-inflammatory drugs can lower serum PSA levels 5.
- A study on the cost-effectiveness of BTK inhibitors, including ibrutinib, in the treatment of relapsed or refractory mantle cell lymphoma does not mention the effect of ibrutinib on PSA levels 4.
- A study on the effects of tyrosine kinase inhibitors on PSA titers found that nilotinib and imatinib can decrease PSA expression in prostate cancer cell lines, but it does not mention ibrutinib specifically 2.